文献速递胸部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

非肺原发灶的放射抵抗性肺寡转移和寡进展病灶:组织学与剂量分割对放疗后局部控制的影响

Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy.
PubMed 文献 · Adv Radiat Oncol · 2024-03-21

本研究在单一医疗系统内回顾2013至2020年因非肺原发灶的1至5个肺寡转移或寡进展病灶接受放疗的患者,比较放射抵抗性与非放射抵抗性原发灶的局部控制,并分析BED10与局部无复发生存的关系。114例中73例为放射抵抗性原发灶,中位随访59.6个月,放射抵抗性转移灶局部失败率24.7%高于非放射抵抗性的2.4%(P=0.004),BED10≥100 Gy与局部复发风险降低相关。

要点

  • 放射抵抗性原发灶肺转移放疗后局部失败18/73(24.7%),非放射抵抗性为1/41(2.4%),log-rank P=0.004。
  • 放射抵抗性转移灶中结直肠癌局部失败12/41(29.2%),其他原发灶6/32(18.8%),log-rank P=0.018。
  • 单因素分析BED10≥100 Gy与更高LRFS相关(HR 0.263,95%CI 0.105-0.656,P=0.004),多因素分析未达统计学显著。

核心结论

  • 大多数非肺原发灶的肺转移放疗后局部控制令人鼓舞,即使许多原发灶经典上被认为放射抵抗。
  • 结直肠原发灶的肺转移可能受益于测试额外策略,如切除或同步全身治疗联合放疗。

研究设计与样本

  • 在单一医疗系统内识别2013至2020年因非肺原发灶的1至5个肺寡转移或寡进展病灶接受放疗的患者。
  • 放射抵抗性原发癌包括结直肠癌、子宫内膜癌、肾细胞癌、黑色素瘤和肉瘤;非放射抵抗性原发癌包括乳腺、膀胱、食管、胰腺和头颈部癌。
  • 采用Kaplan-Meier估计、log-rank检验和多因素Cox比例风险回归比较局部无复发生存(LRFS)、新转移无生存、无进展生存和总生存。

主要发现

  • 114例患者中73例为放射抵抗性原发癌,中位总剂量50 Gy(IQR 50-54 Gy),中位分次数5次(IQR 3-5),中位随访59.6个月。
  • 非放射抵抗性转移患者41例中1例(2.4%)发生局部失败,放射抵抗性转移患者73例中18例(24.7%)发生局部失败(log-rank P=0.004)。
  • 放射抵抗性转移中,结直肠癌患者41例中12例(29.2%)发生局部失败,其他原发灶32例中6例(18.8%)发生局部失败(log-rank P=0.018)。
  • 单因素分析中BED10≥100 Gy与更高LRFS相关(HR 0.263,95%CI 0.105-0.656,P=0.004),结直肠原发灶与更低LRFS相关(HR 3.060,95%CI 1.204-7.777,P=0.019),但多因素分析未达统计学显著。
  • 结直肠原发灶患者中,多因素分析显示BED10≥100 Gy与更高LRFS相关(HR 0.266,95%CI 0.072-0.985,P=0.047)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated whether pulmonary metastases from historically considered radioresistant primaries would have inferior local control after radiation therapy than those from nonradioresistant nonlung primaries, and whether higher biologically effective dose assuming alpha/beta=10 (BED10) would be associated with superior local control. METHODS AND MATERIALS: We identified patients treated with radiation therapy for oligometastatic or oligoprogressive pulmonary disease to 1 to 5 lung metastases from nonlung primaries in 2013 to 2020 at a single health care system. Radioresistant primary cancers included colorectal carcinoma, endometrial carcinoma, renal cell carcinoma, melanoma, and sarcoma. Nonradioresistant primary cancers included breast, bladder, esophageal, pancreas, and head and neck carcinomas. The Kaplan-Meier estimator, log-rank test, and multivariable Cox proportional hazards regression were used to compare local recurrence-free survival (LRFS), new metastasis-free survival, progression-free survival, and overall survival. RESULTS: Among 114 patients, 73 had radioresistant primary cancers. The median total dose was 50 Gy (IQR, 50-54 Gy) and the median number of fractions was 5 (IQR, 3-5). Median follow-up time was 59.6 months. One of 41 (2.4%) patients with a nonradioresistant metastasis experienced local failure compared with 18 of 73 (24.7%) patients with radioresistant metastasis (log-rank P = .004). Among radioresistant metastases, 12 of 41 (29.2%) patients with colorectal carcinoma experienced local failure compared with 6 of 32 (18.8%) with other primaries (log-rank P = .018). BED10 ≥100 Gy was associated with decreased risk of local recurrence. On univariable analysis, BED10 ≥100 Gy (hazard ratio [HR], 0.263; 95% CI, 0.105-0.656; P = .004) was associated with higher LRFS, and colorectal primary (HR, 3.060; 95% CI, 1.204-7.777; P = .019) was associated with lower LRFS, though these were not statistically significant on multivariable analysis. Among colorectal primary patients, BED10 ≥100 Gy was associated with higher LRFS (HR, 0.266; 95% CI, 0.072-0.985; P = .047) on multivariable analysis. CONCLUSIONS: Local control after radiation therapy was encouraging for pulmonary metastases from most nonlung primaries, even for many of those classically considered to be radioresistant. Those from colorectal primaries may benefit from testing additional strategies, such as resection or systemic treatment concurrent with radiation.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Verma N, Laird JH, Moore NS, et al. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Adv Radiat Oncol. 2024. PMID: 38699671. doi:10.1016/j.adro.2024.101500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。